**Programma Webinar ‘’Decision-making for individual patients: Clinical experience, evidence or both?’’**

 **Programma:**

17:00 **Introduction Dr Slamon** Voorzitter

17:05 **Statement l:** Voorzitter

“*Evidence based medicine is the golden standard for oncologists”*

17:15 **Presentation** Slamon

17:25 **Statement ll:**

*” It is possible to treat all my mBC patiënts with 1 CDK4/6 inhibitor (who are eligible)*”

**Statement lll:**

*”The most important thing in the treatment of patiënts is to live longer with a high quality of life”* Voorzitter

17:35 **Presentation** Slamon

17:45 **Repeat** **Statement l:**

“*Evidence based medicine is the golden standard for oncologists”*  Voorzitter

17:55 **Open discussion + Statements** All

**Statement lV:** *“The most important parameter in treatment choice is significant OS data”*

**Stelling V:** *“You need experience with all the CDK4/6 inhibitors to make a goodtreatment choice for the individual patiënt ”*

**Stelling Vl:** *“Significant OS data have the same value as non-significant OS data, most important is that there is clinical relevant”*

**Stelling Vll:** *“mBC patiënts involved enough in their treatment choice”*

18:30 **Evaluation** Slamon

International perspective/ scientific background

18:40 **Closing** Voorzitter

**Topics Presentation Slamon:**

Essential difference between OS and PFS, time to chemo; what does it mean in daily practice

Class effect?

Clinical relevance: how visible when you see a patiënt

Time to delay chemo

Quality of life

Patiënt